Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Mar 27, 2019
Alzheimer’s is one of the diseases which are irreversible and untreatable. With causes still unknown adds to the further conundrum. But for more than two decades now Scientists from everywhere have been working on the “amyloid hypothesis". It has been a long-standing theory that brains of the people affected ...
Read More...
Feb 16, 2018
Vertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko's annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaf...
Read More...
Sep 28, 2017
Another flop for Alzeimer’s as Late Stage drug of AxovantSciences fails in trial Axovant Sciences has reported the failure of their late-stage trial involving the testing of its pill Intepirdinecould not suppress Alzheimer's symptoms in participants of the trail. The news had plunged the Wall Street into another wav...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper